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Abstract
Rationale Schizophrenia is associated with impairments in cognitive functioning yet there are no approved drugs to treat these
deficits.
Objectives Based on animal models, we investigated the potential for roflumilast, a selective inhibitor of phosphodiesterase type
4 (PDE4), to improve cognition, which may act by increasing intracellular cyclic adenosine monophosphate in brain regions
underlying cognitive deficits in schizophrenia.
Methods This study consisted of a randomised, double-blind, placebo-controlled, crossover design involving 15 schizophrenia
patients. In 3 treatment periods, patients were given 8 days of placebo or one of the two doses of roflumilast (100 and 250 μg
daily) with 14 days of washout between treatments. The primary endpoints were dorsolateral prefrontal cortex (DLPFC)
activation during a visuospatial working memory task measured with fMRI on dosing day 8 and verbal memory and working
memory performance change from baseline to day 8. Least square mean change scores were calculated for behavioural outcomes;
fMRI data were analysed in SPM12 with bilateral DLPFC as regions of interest.
Results Verbal memory was significantly improved under 250 μg roflumilast (effect size (ES) = 0.77) compared to placebo.
fMRI analyses revealed that increasing dose of roflumilast was associated with reduction of bilateral DLPFC activation during
working memory compared to placebo, although this was not statistically significant (ES = 0.31 for the higher dose). Working
memory was not improved (ES = 0.03).
Conclusions Results support the mechanistic validation of potential novel strategies for improving cognitive dysfunction in
schizophrenia and suggest that PDE4 inhibition may be beneficial for cognitive dysfunction in schizophrenia.
Trial registration NCT02079844.
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Introduction
Patients with schizophrenia commonly experience positive
symptoms such as hallucinations and delusions and negative
symptoms such as lack of motivation and flattening of affect.
In addition, patients also suffer from impairments in cognitive
functioning, which are often profound and evident across a
range of cognitive domains including learning, attention,
memory and executive function (Heinrichs and Zakzanis
1998). Despite the prevalence of these cognitive deficits, there
are currently no approved treatments for cognitive impair-
ments in schizophrenia. Cognitive impairments are highly cor-
related with functional disability (O’Carroll 2000; Green et al.
2004) and in some domains to a greater degree than clinical
symptoms (Bowie et al. 2006), so there is a significant need to
develop novel therapeutic interventions to improve cognition
in these patients (Gilleen et al. 2014; Gilleen 2017).
Many compounds and non-pharmacological techniques
have been tested for their potential to treat cognitive deficits
in schizophrenia (Wallace et al. 2011). While there have been
some promising results, the dominant picture is of mixed find-
ings and overall modest effect sizes. Pharmacological ap-
proaches include the use of agonist compounds, which may
be useful in the short term, but present a theoretical limitation
of adaptation of the neurotransmitter system or tolerance at the
target receptor site. Compounds that indirectly alter target
neurotransmitter systems may offer a more feasible approach.
These include allosteric modulators, or those that inhibit en-
zymes, which breakdown components of neural signalling
cascades.
Recently, there has also been considerable interest in the
potential for inhibitors of the enzyme phosphodiesterase
(PDEs) to improve cognitive functioning. PDEs are a large
family of intracellular enzymes that hydrolyse the cyclic nu-
cleotides cyclic adenosine monophosphate (cAMP) and/or cy-
clic guanosine monophosphate (cGMP). cAMP plays an im-
portant role as a second messenger molecule controlling mul-
tiple cellular processes (Conti and Jin 1999). Currently, 11
PDE families (PDE1–PDE11) have been identified that differ
in substrate specificity, sensitivity to inhibitors and expression
in different cell types. Areas of high PDE localisation are
widespread, including hippocampus, prefrontal cortex, stria-
tum and amygdala supporting a role for these enzymes in
cognition (Wallace et al. 2011; van der Aart et al. 2017).
Within the PDE family, PDE4 holds specificity for cAMP
and inhibition of this enzyme has demonstrated some potential
for improving cognition. Rolipram, a highly selective inhibi-
tor of PDE4 (Conti and Jin 1999), which enhances intracellu-
lar availability of cAMP (Pérez-Torres et al. 2000), has been
shown to improve memory in rats (Barad et al. 1998;
Hosseini-Sharifabad et al. 2012; Rutten et al. 2006;
Vanmierlo et al. 2016) and reverse MK-801-induced (Zhang
et al. 2000) and scopolamine-induced (Egawa et al. 1997;
Zhang et al. 2000) deficits in working memory, latent inhibi-
tion (Davis and Gould 2005), as well as scopolamine-induced
deficits in short-term memory (Imanishi et al. 1997; Rutten
et al. 2009; Zhang et al. 2000). Rolipram attenuates PCP-
induced impairments in object retrieval in monkeys (Rutten
et al. 2008), and cognitive flexibility in rodents (Rodefer et al.
2012). Rolipram is a non-selective PDE4 inhibitor, and these
effects may be due to the involvement of cAMP in memory as
PDE4A, 4D and to a lesser extent 4C are expressed in rat
hippocampal CA1 (Peng et al. 2014). Rolipram increases
cAMP response in hippocampal slices and serves to facilitate
persistent long-term potentiation in CA1 (Barad et al. 1998)
and may do so by lowering the threshold at which LTP occurs
(Bach et al. 1999).
In humans to date, there is no published assessment of the
ability of rolipram to improve cognition, which may in part be
due to its emetic side effects likely, in turn, due to its non-
selectivity. Another PDE4 inhibitor, roflumilast, currently
used to treat chronic obstructive pulmonary disease, has also
shown potential to be a cognitive enhancer and has a more
favourable side-effect profile perhaps attributable to its greater
relative selectivity (for PDE4B/D). Although roflumilast has
been used in fewer neurological studies than rolipram, the
reported effects to date are favourable. Roflumilast (and
rolipram) significantly reverses time-induced memory deficits
in a novel object recognition task (Jabaris et al. 2015) and also
enhances spatial Y-maze performance in mice (Vanmierlo
et al. 2016). In healthy volunteers, Van Duinen et al. (2015)
demonstrated that a single dose of 100 μg roflumilast im-
proved verbal memory and P600 (late event related potentials)
during verbal learning significantly more than placebo.
Further, the same group reported that roflumilast improved
verbal learning in elderly healthy volunteers (Van Duinen
et al. 2017).
Cognitive deficits in schizophrenia are broad and notably
include prefrontal dysfunction in addition to hippocampal-
dependent memories (Heinrichs and Zakzanis 1998).
Dopamine dysfunction has also been implicated in the fron-
tally mediated deficits through the dopamine D1 receptor
(Goldman-Rakic et al. 2004). D1R binding in PFC is reduced
in schizophrenia, and this reduction is associated with poorer
cognitive performance (Okubo et al. 1997). PDE4 can modu-
late dopamine signalling via its effects on cAMP, which is
increased with dopamine D1 receptor agonism (Cooper
2003). Indeed, PDE4 is co-expressed with DARPP-32 in D1
receptor-positive cortical pyramidal neurons and modulates
the level of D1 receptor signalling and DARPP-32 phosphor-
ylation in the frontal cortex (Kuroiwa et al. 2012). As working
memory is impaired in schizophrenia (Heinrichs and Zakzanis
1998), is functionally subserved in part by prefrontal D1
(Goldman-Rakic et al. 2004) and is disrupted by dysregulation
of cAMP signalling (Taylor et al. 1999), roflumilast may be
expected to improve cognition via this pathway.
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In this study, we aimed to demonstrate that roflumilast, as
an add-on to second-generation antipsychotics (SGAs), would
improve working memory and episodic memory functioning
in schizophrenia patients. We reasoned that the domains of
working memory and verbal episodic memory, consistently
impaired in schizophrenia, would be sensitive to modulation
of PDE4 activity based on previous animal studies and the
known role of cAMP in these processes. We included func-
tional imaging of a working memory task to test the hypoth-
esis that prefrontal cortex activity would be modulated by
roflumilast, and to our knowledge, this is the first three-
period crossover fMRI neuroimaging study designed to assess
a cognitive enhancer in schizophrenia. We anticipated that
roflumilast would enhance cognitive performance compared
to placebo. Specifically, we hypothesised that there would be a
significantly greater positive change in performance of verbal
episodic memory (as measured by the HVLT) and working
memory (as measured by the Spatial Span task), and signifi-
cantly reduced dorsolateral prefrontal cortex activity during
spatial working memory (as measured by the Dot Task with
fMRI) following 8 days of treatment with roflumilast com-
pared to 8 days with placebo. We also additionally explored
dose-response effects of roflumilast for these cognitive and
neural outcomes.
Method
Design
This was a phase 1, randomised, double-blind, placebo-con-
trolled, single-site, three-period crossover study to evaluate
the effect of roflumilast as an add-on to SGA in attenuating
cognitive deficits associated with schizophrenia. In each of the
three periods, placebo and 100 or 250 μg roflumilast were
administered once daily to patients with schizophrenia for
eight consecutive days to achieve steady state (Fig. 1). The
time course of study participation was consistent and
conformed to Fig. 1 for all participants. All patients received
all doses, and the treatment order was determined by random
allocation to one of three treatment sequences according to a
Latin Square design (ABC, BCA or CAB), with a 2-week
wash-out between phases (see Table 1).
Cognitive testing with the Hopkins verbal learning test-
revised (HVLT-R) and spatial span (SS) from the MCCB
MATRICS test battery (Nuechterlein et al. 2008) was per-
formed on the first (pre-drug on D1) and last day (D8 post-
drug) of each phase to assess change in cognition, and fMRI
was conducted on the eighth day of each phase (see fig. 1).
One week prior to the first drug or placebo testing phase, all
participants underwent two practice training sessions for the
cognitive tests and an fMRI familiarisation session. Prior
task administration is a standard approach to minimise, or
‘wash-out’, practice or learning effects. These effects were
further reduced by using the five available parallel versions
of the HVLT-R (forms 1, 3, 4, 5 and 6), and the order of
HVLT form adminis t ra t ion was randomised and
counterbalanced across participants. The DOT task trial-set
is randomly generated with each test administration. For the
spatial span task, no parallel versions exist however as there
was at least 7 days between assessments trial-specific reten-
tion (learning effects) would not be expected to occur for
such complex spatial sequences. There were three outcome
measures: change in accuracy on the HVLT-R, span on the
SS and neural activity change during a spatial working mem-
ory test (the Dot Task (Marquand et al. 2011)) as measured
with fMRI. Performance on the Dot Task was trained to
achieve a 70% correct threshold, and only correct trials
(hence successful working memory) were included in the
analysis. FMRI was carried out while subjects performed
the Dot Task in the MR scanner while the other cognitive
tasks, the HVLT and spatial span task, were performed just
prior and outside the scanner.
This study took place at the Institute of Psychiatry,
Psychology and Neuroscience, Kings College London. This
research was conducted in accordance with the protocol pro-
cedures complied with the Declaration of Helsinki, the
International Conference on Harmonisation (ICH) E6 GCP
guidance, and all applicable local or regional regulatory re-
quirements. The study was pre-registered with clinicaltrials.
gov (identifier: NCT02079844), and hospital ethics approvals
were given by NRES Committee South Central Berkshire
(reference 12/SC/0443).
Fig. 1 Showing study schedule
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Participants
Patients who had consented to be contacted about participat-
ing in research were recruited from local outpatient services.
Following the study inclusion/exclusion criteria, men or wom-
en, aged 18 to 60 years, who met Diagnostic and Statistical
Manual of Mental Disorders, 5th Edition (DSM-5), criteria for
schizophrenia, and who were receiving stable doses of
second-generation antipsychotics for at least 2 months prior
to screening (see supplementary materials for inclusion/
exclusion criteria) were eligible to take part. Twenty-one pa-
tients were consented and randomised to one of the treatment
groups. Participants were randomised to one of three treatment
sequences according to a blinded computer-generated alloca-
tion schedule. Six did not complete the study: five participants
withdrewwithout reason, and one was unable to attend dosing
and so was withdrawn. Demographics and clinical informa-
tion for the 15 participants who completed are shown in
Table 2, and additional information on participants is shown
in supplementary materials. Only data from completers is re-
ported. Seven participants were receiving olanzapine (2 at
20 mg, 2 at 10 mg, 1 at 15 mg, 1 at 10 mg, 1 at 2.5 mg), four
were receiving aripiprazole (2 at 20 mg, 1 at 15 mg, 1 at
10 mg), one quetiapine 300 mg, one paliperidone 50 mg and
two risperidone depot 25 mg.
Dose
It has been demonstrated that single doses of roflumilast
100 μg (but not 300 or 1000 μg) administration improves
episodic memory in both healthy volunteers; with the same
pattern—single dose 100μg (but not 300 or 1000μg)—show-
ing significant effects on P600 values with EEG (24,25, 40).
In following, 100 and 250 μg in multiple dosing to achieve
steady-state condition were chosen for this study to explore
the effective dose window in patients with schizophrenia.
Dosing on all days took place at site in front of a research
team member to ensure compliance—confirmed post hoc
via pharmacokinetic/metabolite analysis of blood samples.
Plasma concentrations, roflumilast exposure and safety data
are reported in supplementary materials. Both doses were
compared to placebo. Blinding and randomisation procedures
were conducted by Quintiles CRO Ltd. Blindings for this
study were not broken for any participant.
Measures
Two memory subtests from the MATRICS Consensus
Cognitive Battery (MCCB (Nuechterlein et al. 2008)) were
administered:
The Hopkins verbal learning test-revised (Brandt
and Benedict 2001)
The Hopkins verbal learning test-revised (HVLT-R) is a sub-
test of the MATRICS Consensus Cognitive Battery (MCCB
(Nuechterlein et al. 2008)). It assesses verbal memory and
consists of a list of 12 words from 3 taxonomic categories.
The words were presented orally, and the participants are
asked to recall as many words as possible after each of three
Table 1 Treatment sequences
Sequence Period 1 Period 2 Period 3
ABC (N = 5) Placebo + SGA Roflumilast 100 μg + SGA Roflumilast 250 μg + SGA
BCA (N = 5) Roflumilast 100 μg + SGA Roflumilast 250 μg + SGA Placebo + SGA
CAB (N = 5) Roflumilast 250 μg + SGA Placebo + SGA Roflumilast 100 μg + SGA
Table 2 Participant demographic
and clinical information Mean (SD)
Age (years) 40.5 (10.5)
Gender (male/female) 10:5
Ethnicity 9 Black British, 4 White British, 2 British Asian
Age of illness onset (years) 32.7 (6.2)
Age of illness duration (months) 170.9 (116.3)
Time on current antipsychotic treatment (months) 74.1 (56.6)
Baseline PANSS Total 59.9 (16.1)
Baseline PANSS Positive 14.3 (4.3)
Baseline PANSS Negative 15.1 (5.2)
Baseline PANSS General 30.5 (8.1)
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trials. The key outcome variable for the HVLT-R was the total
number of correct responses over three trials. The test was
administered on day 1 (pre-drug) and day 8 (post-drug), and
each drug period made use of the alternate HVLT-R forms
from the MATRICS to avoid practice effects.
The spatial span test (Wechsler memory scale 3rd edition;
Wechsler 1997)
The spatial span test assesses working memory. Participants are
presented with a board containing blue blocks arranged in an
irregular pattern. The rater taps out a pattern on the blocks and
participants are taskedwith tapping the same pattern in response.
Trial spans become longer in length and also consist of both
forward and reverse patterns, the latter requiring patients to tap
in the reverse order to the administrator. Scores are the sum of
the correct responses in both the forward and backward trials.
fMRI
The DOT task
In the DOT task (see Fig. 2), a rewarded delayed-response
working memory task (Marquand et al. 2011), participants
are instructed to remember the spatial location of a target
stimulus (a dot) relative to a fixation cross after a delay period,
which includes a noise mask (numerous moving dots). Half of
the 40 trials carried a monetary reward, indicated by the colour
of the stimulus, and the order of the trials was randomised and
counterbalanced across subjects. In each trial, the target stim-
ulus was presented for 750 ms (encoding), followed immedi-
ately by a mask for a further 750 ms to disrupt visual iconic
memory; after a 7- or 9-s interval (delay), the target stimulus
and a distracter stimulus are presented, and participants indi-
cated which of the stimuli matches the target location by a left-
or right-button press on a two-button response box (retrieval;
2 s). Feedback indicating success or failure is provided at the
end of each trial. Patients received training on the task to
ensure they understood the instructions, were able to respond
appropriately and could achieve a threshold performance of
70% correct trials—well above chance. Only correct trials
were used in the analysis as we were interested in successful
spatial working memory (evident from correct trials only)—
hence performance changes per se were not examined, only
BOLD response changes during spatial working memory.
FMRI was only conducted on D8 (post-drug), and these ses-
sions were compared between drug arms. Strict criteria were
used for acceptance of valid data available in all three
sessions.
Symptom measures
Symptoms were assessed at days 1 and 8 using the PANSS
(Kay et al. 1987), although the study design was focussed on,
and powered for, the cognitive outcomes.
Statistical analysis
Statistical analyses were performed to examine the effect of
each dose of drug and placebo on change in cognitive test
scores from day 1 (baseline) to day 8 (post-drug assessment)
for the endpoints involving cognitive test results relative to
change in the placebo phase from day 1 (baseline) to day 8
(post-drug assessment), and by day 8 comparison for the fMRI
endpoints. Data processing and voxelwise brain image analy-
sis was performed by the investigators, with the analysis of the
primary endpoints performed by an independent statistician.
Cognition
Pairwise comparisons were made between each roflumilast
dose level and placebo using LS means estimated via analysis
of variance (ANOVA) with sequence, period and treatment as
fixed effects and subject nested within sequence as a random
effect. The effect size for each roflumilast dose level was
calculated using Cohen’s d from which an effect size of 0 to
0.2 is considered small, 0.3 to 0.7 is considered moderate, and
≥ 0.8 is considered large.
fMRI
MRI data acquisition We collected a high-resolution T1-
weighted image on one session for each participant, for nor-
malisation to a standard space (TR = 7312 ms, TE = 3.016 ms,
Fig. 2 Showing task schematic
for the Dot Task
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FoV 270 mm, voxel size 1.05 × 1.05 × 1.2 mm, 196 slices,
TI = 400 ms). The functional time series used the following
parameters (TR = 2000 ms, TE = 30 ms, FoV 211 mm, voxel
size 3.75 × 3.75 × 3.3 mm, 39 slices).
fMRI and roflumilast The fMRI task data acquisition started
5 h after day 8 dosing. The Tmax is up to 3 h after ingestion of
a single dose and its N-oxide metabolite demonstrates a
plateau-like Tmax after about 8 h. The median effective
half-life of roflumilast is 17 h. Steady-state plasma concentra-
tions following repeated dosing with 500 μg Roflumilast is
estimated to be reached after approximately 4 days (83 h) for
roflumilast and after 6 days (148 h) for theN-oxidemetabolite.
Roflumilast and its N-oxide show linear repeated-dose phar-
macokinetics over the dose range of 250 to 1000 μg. Thus,
assessment after 8 days of treatment ensured steady-state plas-
ma concentrations required for cognitive testing.
fMRI modelling Preprocesing steps are reported in the
Supplementary materials. Single-subject, single-session
fixed-effects GLM analysis was conducted to model re-
sponses during the DOT task. The DOT task consists of
three parts: encoding, delay and retrieval, and additionally,
trials were either rewarded or unrewarded. Thus, the fol-
lowing regressors were modelled: non-rewarded encoding
and delay, non-rewarded retrieval, non-rewarded feed-
back, rewarded encoding and delay, rewarded retrieval
and rewarded feedback. Because of the proximity in time
and the brief, fixed presentation time of the cues, the
encoding and delay periods were modelled together. The
six movement regressors from the motion correction were
also included in the model. A high pass filter of a period
of 128 s was applied to the model to eliminate low-
frequency signals such as scanner drift. For the purposes
of reporting the data here, contrasts for the encoding and
delay period were combined across the rewarded and non-
rewarded trials as the primary outcomes were based on
working memory-related activity.
The individual contrast maps from the first level were en-
tered into a second level, random-effects analysis with subject
as the random effect and session (drug/placebo) as a within-
subject effect. Linear contrasts were used to describe the main
effect of task across all drug conditions and the effect of
roflumilast on the a priori defined region of interest.
fMRI performed well across participants in relation to the
cognitive task and data collected, although data from some
were removed due to poor quality. Quality was assessed for
the fMRI data by visually inspecting coverage within the field
of view and calculating movement. Excessive movement (> 1
voxel > 20% volumes) in any one session resulted in removal
of the participant from the fMRI analysis. A high response rate
was required for the task (> 60%), and no participant was
removed due to low response rate.
Regions of interest (ROI)
A dorsolateral prefrontal cortex (DLPFC) ROI was chosen
due to its known involvement in working memory (Curtis
and D’Esposito 2003) defined as 6-mm spheres centred on
the peak co-ordinates from Marquand et al. (2011) (Left −
43, 33, 25, Right 38, 44, 32), which utilised the same task.
Results
HVLT-r
LS mean HVLT total scores on day 8 (compared to Day 1)
were increased with roflumilast 100 and 250 μg (0.27 (SE =
1.06) and 1.07 (SE = 1.08), respectively) and decreased with
placebo (− 1.67, SE = 1.08) (see Table 3). LS mean differ-
ences in change from baseline between high-dose roflumilast
and placebo were statistically significant (p = .044, ES = 0.77
(large effect size)), but not between low-dose roflumilast and
placebo (p = .14, ES = 0.55 (medium effect size)). We also
conducted an ITT (Intention To Treat) analysis which revealed
the following effects: 100 μg (N = 17) vs placebo (N = 16):
ES = .45 (95% CI interval = − 0.25 to 1.14); and 250 μg
(N = 16) vs placebo: ES = 0.55 (95% CI interval = − 0.16 to
1.26). These differences were not significantly different.
Post hoc examination of the three HVLT trials revealed that
performance on the high-dose roflumilast and placebo was
maximally different on the third and last recall test of the three
HVLT-Rword list repetitions (effect size for trial 1 = 0.32, trial
2 = 0.47, trial 3 = 0.73).
Spatial span
LS mean total score change from D1 to day 8 with roflumilast
100 and 250 μg were 0.07 (SE = 0.51) and − 0.13 (SE = .52),
respectively, while scores decreased with placebo (− 0.20,
SE = 0.52). Change under both roflumilast doses were not
significantly different to placebo (low dose p = .74; high dose
p = .93). An ITT analysis (placebo: N = 16, 100 μg N = 17,
and 250 μg N = 16) also revealed no significant drug effects
vs placebo (100 μg (N = 17) vs placebo (N = 16): ES = 0.11
(95% CI interval = − 0.57 to 0.79), and 250 μg (N = 16) vs
placebo: ES = 0.06 (95% CI interval = − 0.63 to 0.76).
fMRI
The DOT task
Complete data were acquired for ten participants. Participants
were as evenly distributed across the treatment orders as pos-
sible. For the comparison of placebo with 100 and 250 μg,
there was change of activity with effect sizes of − 0.03 and −
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0.671, with p values of 0.948 and 0.154 respectively. A
voxelwise analysis was additionally conducted, and this again
showed a reduction in activity from placebo to 250 μg
roflumilast (shown in Fig. 3a, b) although this did not survive
FWE-correction for multiple comparisons in the DLPFC. An
additional exploratory whole-brain analysis was performed,
and this revealed that no other brain regions were significantly
affected by roflumilast; thus, no changes outside the DLPFC
were observed. A separate analysis of the same data but in-
cluding all 13 patients who completed the task (at any time
point) showed effect sizes of − 0.006 for 100 μg (p = .98) and
0.500 for 250 μg (p = 0.082). The mean difference in BOLD
response for the low and high doses is illustrated in Fig. 3c.
While these analyses are in line with our prediction of reduced
activity in the DLFPC with roflumilast, the differences were
not significant. Post hoc analyses of the rewarded and unre-
warded trials separately showed the same pattern of results:
less activity associated with the high dose, most with placebo
and the low dose producing intermediate activity.
Behaviourally, as participants were trained to perform well
on the task (to a threshold of ~ 70%) and only correct trials
were used in the analysis performance was intended to be
matched across treatment arms. As shown in Table 3, this
was the case, and differences were not statistically different.
Symptom ratings
PANSS ratings did not change from day 1 to 8 for either dose
of drug on either the positive or negative scale (ps > 0.434).
Fig. 3 Showing DOT task fMRI
results. a showing brain regions
where activity was lower with
250 μg (green; a priori ROIs in
yellow). b showing extracted beta
coefficients of activity for the
peak voxel within the a priori ROI
at each drug dose (n = 10). c is a
histogram showing the LS mean
difference from placebo and 95%
confidence intervals for all 13
participants who completed the
DOT task
Table 3 Mean behavioural performance scores (sds) for the cognitive tasks at each drug level
Dose Placebo Low dose High dose
Day D1 D8 D1 D8 D1 D8
HVLT-R 21.93 (4.77) 20.20 (4.25) 20.33 (5.41) 20.60 (5.53) 19.53 (6.55) 20.60 (6.06)
Spatial Span 14.67 (3.96) 14.47 (4.14) 14.47 (3.83) 14.40 (3.72) 14.73 (3.90) 14.60 (3.78)
Dot Task percent accuracya 69.41 (16.39) 69.01 (19.15) 70.71 (15.14)
D1 day 1, D8 day 8, HVLT Hopkins verbal memory test
a Dot Task was only done at D8
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Discussion
This study tested the hypothesis that the addition of
roflumilast, a PDE4 inhibitor, would improve cognitive func-
tion and modulate frontal brain activity in patients with
schizophrenia treated with atypical antipsychotics. The perfor-
mance on verbal learning from the HVLT was significantly
improved with the higher dose of roflumilast compared to
placebo; however, working memorymeasured with the spatial
span test did not show improvement. Reductions in PFC ac-
tivity during working memory were evident with increasing
doses of roflumilast in bilateral DLPFC, and the effect size for
the higher dose was 0.5.
Verbal learning
There is considerable preclinical evidence suggesting that in-
hibition of the PDE4 enzyme improves cognition, particularly
memory processes (Bach et al. 1999; Barad et al. 1998;
Hosseini-Sharifabad et al. 2012; Rodefer et al. 2012; Rutten
et al. 2006; Rutten et al. 2008; Rutten et al. 2009; Vanmierlo
et al. 2016; Zhang et al. 2000). Performance on verbal list
learning was significantly enhanced by roflumilast in patients
with schizophrenia—and these effects were greatest on the
third and final learning presentation. Strikingly, Van Duinen
et al. (2018) have also recently reported improvement in ver-
bal learning performance following a single-dose 100 μg of
roflumilast in healthy adults—and also showing greatest ef-
fects on the third trial in healthy adults as demonstrated here.
The P600 peak as measured by EEG during verbal learning
was also significantly increased, again only on the third trial at
100 μg, not at 300 or 1000 μg, of roflumilast. The authors
suggest these findings may indicate that roflumilast affects
information processing during memory (word) encoding.
There is now emerging and converging evidence that
PDE4 inhibition can enhance memory via its action on long-
term potentiation (LTP). Rolipram specifically induces late-
phase LTP (L-LTP) not early-phase LTP (E-LTP) in rat hippo-
campus (Barad et al. 1998), and similarly specifically modu-
lates late-long-term memory (LTM) not early-LTM (Rutten
et al. 2009). It has been proposed that increasing cAMP sig-
nalling may improve memory by raising the probability that
long-lasting synaptic plasticity occurs (Barad et al. 1998;
Blokland et al. 2012). In line with this, mice with impaired
long-term object recognition, due to being carriers of truncat-
ed CREB-binding protein, show reversal of deficits with
rolipram (Bourtchouladze et al. 2003). In humans, the hippo-
campus is active during memory, which requires longer-term
storage, including verbal learning (Johnson et al. 2001). Thus,
as potential for LTP will be maximal with an increased num-
ber of stimuli presented over a time period, elevation of L-
LTP/L-LTM by roflumilast is a potential neurobiological
mechanism by which verbal learning performance improve-
ments may occur.
Working memory
Roflumilast was associated with reduced cortical demands
during spatial working memory assessed using fMRI. This
modulation was dose-dependent with a medium effect size
for the higher dose, suggesting improved neural efficiency.
We proposed that roflumilast would improve working memo-
ry as PDE4 inhibition increases intracellular cAMP levels in
striatum and frontal cortex. These alterations increase dopa-
mine synthesis and turnover in striatum and enhance the do-
pamine D1 receptor/PKA/DARP-32 signalling cascade in
frontal cortex. Inhibition of PDE4 by rolipram increases do-
pamine D1 receptor signalling in cortical pyramidal neurons
(in mouse) in frontal cortex (Kuroiwa et al. 2012), and dopa-
mine D1 receptor signalling is known to improve working
memory performance in rodents and non-human primates
(Goldman-Rakic et al. 2004). The preclinical evidence also
indicated that PDE4 inhibition reverses MK-801-induced
(Vanmierlo et al. 2006) and scopolamine-induced (Egawa
et al. 1997) deficits in working memory. As an example, acti-
vation of NMDA receptors produces a CA2-dependent in-
crease in cAMP that may play a role in the induction of LTP
in CA1 of the hippocampus (Zhang et al. 2000).
Roflumilast did not, however, lead to significant change in
cognitive performance on spatial span compared to placebo at
either dose. The pattern of data in the prefrontal cortex fits
with previous neuroimaging studies of catecholaminergic
stimulant medication (e.g., Mehta et al. 2000) with reductions
in task-related activity accompanied by improvements, or
even lack of significant change in performance. Future studies
could investigate the specific PDE4 neurotransmitter interac-
tions, which may account for pro-cognitive effects of PDE4
inhibition in working memory, changes in neural efficiency,
and other cognitive processes.
Limitations
The main limitation of this mechanistic study was the relative-
ly low subject numbers, partly due to attrition because the
patients found the frequency and complexity of assessments
within the study somewhat demanding. As this study is ex-
ploratory in nature, the sample size was not based on statistical
considerations. The sample size is based on the desire to gain
adequate efficacy data on the primary and secondary out-
comes as well as on published literature reporting pro-
cognitive effects of drug candidates using the same pharma-
cological model and similar study. However, using a within-
subject, crossover design rescues some statistical power by
reducing degrees of freedom.
Psychopharmacology
A primary goal of the study was to provide evidence of
improved cognitive function following PDE4 inhibition in
patients for the first time, and to assess the underlying impact
on frontal brain activation, In both respects, it was successful
and demonstrates the utility of combining cognitive and im-
aging markers in studies of novel mechanisms in patient pop-
ulations. Since the outcomes were only measured at one time
point, we are unable to determine if the drug effects are in fact
greater earlier after an acute medication administration, or
alternatively, if longer-term treatment leads to more robust
effects in patients.
The delayed-response working memory fMRI task was
based on one of the most widely used working memory par-
adigms, is sensitive to pharmacological manipulation and in-
corporated reward and no-reward conditions in order to paral-
lel both the human and animal research into working memory
processes. This also allows for secondary analyses to examine
the role of reward; however, there was no differential effect of
roflumilast on reward. This could reflect either a real lack of
effect, or poor sensitivity due to the low sample size.
Additionally, for the purposes of this initial trial, we
minimised the number of endpoints and chose to examine
only the DLPFC during administration of the DOT task as this
aligned with the predicted effects in schizophrenia and the
predicted effects of PDE4 inhibition on the prefrontal activa-
tion seen during the encoding and delay periods on the task;
however, subsequent work could investigate additional brain
regions.
The age at illness onset ranged from 17 to 44 years, and the
mean age of participants was 32 years old which is relatively
later than in other patient studies. An older average age of
patients is, however, more likely to be expected in drug trials
as clinical and medication stability are inclusion criteria, and
this is somewhat more likely in older patients. Despite this, the
higher mean age may also be due to the relatively small sam-
ple size and could potentially limit the generalizability of the
findings to younger onset samples.
The significant mean score differences between high-dose
roflumilast and placebo on the HVLT-Rwere contributed to in
part by a decline over time in the placebo arm.Despite this, the
trend from placebo to high dose was significantly greater im-
provement with the high dose than placebo. Decline in the
placebo group may additionally be attributable to study fa-
tigue, which may be modified in the treatment periods.
Conclusions
Individuals with schizophrenia have significant cognitive def-
icits across many domains of functioning including memory,
learning and working memory. Improvements in cognitive
functioning are associated with better overall outcomes in in-
dividuals with schizophrenia (Bowie et al. 2006), yet there are
no currently approved drugs for the improvement of cognition
in schizophrenia. This study investigated the potential for
roflumilast, a PDE4 inhibitor, to provide pro-cognitive effects
in patients with schizophrenia concurrently treated with
second-generation antipsychotics. The results showed that
high-dose roflumilast significantly improved verbal learning
relative to placebo. There was also a trend for roflumilast de-
creasing activation in the DLPFC during working memory
suggestive of an impact via improving neural efficiency.
These results are in line with previous studies with experimen-
tal animals indicating that PDE4 inhibitionmay improve mem-
ory function through its impact on intracellular mechanisms.
Memory may be enhanced via the effects of cAMP on two
systems—one, fast-acting on prefrontal neurotransmission to
improve online memory processes, and a second, enhancing
the capacity of L-LTP to encode learning targets (Kuroiwa
et al. 2012). In summary, this clinical study provides support
for increasing the use of combined neuroimaging and cognitive
testing to validate models developed in experimental animals.
We suggest that this research also supports further evaluation
and clinical trials of this well-tolerated, off-patent and widely
prescribed treatment as a potentially repurposed medication
from respiratory medicine to neuropsychiatry. It should also
be noted for subsequent studies that cAMP gradients and re-
sponses are highly varied among PDE isoforms (Fertig and
Baillie 2018); thus, future work may better couple specific
targeting of PDE4 subtypes with cognitive effects, potentially
avoiding the need for multiple days of dosing to achieve steady
state, as well as potential optimisation of side-effect profiles.
Acknowledgements Wewould, firstly, like to acknowledge and thank the
patients who participated for the time and effort they gave to the study. We
acknowledge the on-going support from the NIHR-Wellcome Trust King’s
Clinical Research Facility and the National Institute for Health Research
(NIHR) Biomedical Research Centre at South London andMaudsley NHS
Foundation Trust and King’s College London. We also thank South
London and Maudsley NHS Foundation Trust for supporting participant
recruitment. The views expressed are those of the author(s) and not nec-
essarily those of the NHS, the NIHR or the Department of Health.
Funding The funding source for this study was Takeda Pharma A/S,
London.
Compliance with ethical standards
This research was conducted in accordance with the protocol procedures
complied with the Declaration of Helsinki, the International Conference
on Harmonisation (ICH) E6 GCP guidance, and all applicable local or
regional regulatory requirements. The study was pre-registered with
clinicaltrials.gov (identifier: NCT02079844), and hospital ethics
approvals were given by NRES Committee South Central Berkshire
(reference 12/SC/0443).
Conflict of interest SSS has received grant funding for clinical trials
and/or honoraria for educational input from EnVivo Pharmaceuticals,
Takeda, AbbVie and Janssen Pharmaceuticals. He is supported by a
European Research Council Consolidator Award (Grant Number
Psychopharmacology
311686) and the National Institute for Health Research (NIHR) Mental
Health Biomedical Research Centre at South London andMaudsley NHS
Foundation Trust and King’s College London. MAM has acted as a
consultant for Cambridge Cognition, Lundbeck and FORUM pharma-
ceuticals in the past 5 years. He also has or has held research funding
from Shire, Roche, Lundbeck and Takeda in the past 5 years. JG has acted
as consultant for Quintiles CRO Ltd. YF, CD, SK, LV, AR and SCWhave
no disclosures or conflicts of interest to report. TU, GL and FO are
employees of Takeda Development Center Americas, Inc., Chicago,
U.S.A.MT is employed by Eli Lilly, Indianapolis, USA.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
Publisher’s Note Springer Nature remains neutral with regard to juris-
dictional claims in published maps and institutional affiliations.
References
BachME, Barad M, Son H, Zhuo M, Lu YF, Shih R, Mansuy I, Hawkins
RD, Kandel ER (1999) Age-related defects in spatial memory are
correlated with defects in the late phase of hippocampal long-term
potentiation in vitro and are attenuated by drugs that enhance the
cAMP signaling pathway. Proc Natl Acad Sci U S A 96:5280–5285
Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E (1998)
Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates
the establishment of long-lasting long-term potentiation and im-
proves memory. Proc Natl Acad Sci U S A 95:15020–15025
Blokland A, Menniti FS, Prickaerts J (2012) PDE inhibition and cogni-
tion enhancement. Expert Opin Ther Pat 22:349–354
Bourtchouladze R, Lidge R, Catapano R, Stanley J, Gossweiler S,
Romashko D, Scott R, Tully T (2003) A mouse model of
Rubinstein-Taybi syndrome: defective long-term memory is amelio-
rated by inhibitors of phosphodiesterase. Proc Natl Acad Sci U S A
100:10518–10522
Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD (2006)
Determinants of real-world functional performance in schizophrenia
subjects: correlations with cognition, functional capacity, and symp-
toms. Am J Psychiatry 163(3):418–425
Brandt J, Benedict RHB (2001) The Hopkins verbal learning test—re-
vised: professional manual. Psychological Assessment Resources,
Inc., Odessa
Conti M, Jin SLC (1999) The molecular biology of cyclic nucleotide
phosphodiesterases. Prog Nucleic Acid Res 63:1–38
Cooper DMF (2003) Regulation and organization of adenylyl cyclases
and cAMP. Biochem J 375:517–529
Curtis CE, D’Esposito M (2003) Persistent activity in the prefrontal cor-
tex during working memory. Trends Cogn Sci 7:415–423
Davis JA, Gould TJ (2005) Rolipram attenuatesMK-801-induced deficits
in latent inhibition. Behav Neurosci 119:595–602
Egawa T, Mishima K, Matsumoto Y, Iwasaki K, Iwasaki K, Fujiwara M
(1997) Rolipram and its optical isomers, phosphodiesterase 4 inhib-
itors, attenuated the scopolamine-induced impairments of learning
and memory in rats. Jpn J Pharmacol 75:275–281
Fertig BA, Baillie GS (2018) PDE4-mediated cAMP signalling. J
Cardiovasc Dev Dis 5(1):8
Gilleen J (2017) Cognitive enhancement in schizophrenia. In: Keefe
RSE, Reichenberg A, Cummings J (eds) Cognitive enhancement
in CNS disorders and beyond. Oxford University Press, NY, pp
177–212
Gilleen J, Michalopoulou PG, Reichenberg A, Drake R, Wykes T, Lewis
SW, Kapur S (2014) Modafinil combined with cognitive training is
associated with improved learning in healthy volunteers–a
randomised controlled trial. Eur Neuropsychopharmacol 24:529–
539
Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV
(2004) Targeting the dopamine D1 receptor in schizophrenia: in-
sights for cognitive dysfunction. Psychopharmacology 174(1):3–16
GreenMF, Kern RS, Heaton RK (2004) Longitudinal studies of cognition
and functional outcome in schizophrenia : implications for
MATRICS. Schizophr Res 72:41–51
Heinrichs RW, Zakzanis KK (1998) Neurocognitive deficit in schizophre-
nia: a quantitative review of the evidence. Neuropsychology 12:
426–445
Hosseini-Sharifabad A, Ghahremani MH, Sabzevari O, Naghdi N,
Abdollahi M, Beyer C, Bollen E, Prickaerts J, Roghani A,
Sharifzadeh M (2012) Effects of protein kinase A and G inhibitors
on hippocampal cholinergic markers expressions in rolipram- and
sildenafil-induced spatial memory improvement. Pharmacol
Biochem Behav 101:311–319
Imanishi T, Sawa A, Ichimaru Y, Miyashiro M, Kato S, Yamamoto T,
Ueki S (1997) Ameliorating effects of rolipram on experimentally
induced impairments of learning and memory in rodents. Eur J
Pharmacol 321:273–278
Jabaris SGSL, Sumathy H, Kumar RS, Narayanan S, Thanikachalam S,
Babu CS (2015) Effects of rolipram and roflumilast ,
phosphodiesterase-4 inhibitors, on hypertension-induced defects in
memory function in rats. Eur J Pharmacol 746:138–147
Johnson SC, Saykin AJ, Flashman LA, McAllister TW, Sparling MB
(2001) Brain activation on fMRI and verbal memory ability: func-
tional neuroanatomic correlates of CVLT performance. J Int
Neuropsychol Soc 7:55–62
Kay SR, Flszbein A, Opfer LA (1987) The positive and negative syn-
drome scale (PANSS) for schizophrenia. Schizophrenia Bull 13:
261–276
Kuroiwa M, Snyder GL, Shuto T, Fukuda A, Yanagawa Y, Benavides
DR, Nairn AC, Bibb JA, Greengard P, Nishi A (2012)
Phosphodiesterase 4 inhibition enhances the dopamine D1 recep-
tor/PKA/DARPP-32 signaling cascade in frontal cortex.
Psychopharmacology 219:1065–1079
Marquand AF, De Simoni S, Moura J, Mehta MA (2011) Pattern classi-
fication of working memory networks reveals differential effects of
methylphenidate, atomoxetine, and placebo in healthy volunteers.
Neuropsychopharmacol 36(6):1237–1247
Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins
TW (2000) Methylphenidate enhances working memory by modu-
lating discrete frontal and parietal lobe regions in the human brain. J
Neurosci 20:65
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD
et al (2008) The MATRICS consensus cognitive battery, part 1: test
selection, reliability, and validity. Am J Psychiatry 165:203–213
O’Carroll R (2000) Cognitive impairment in schizophrenia. Adv
Psychiatr Treat 6(3):161–168
Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O,
Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y,
Toru M (1997) Decreased prefrontal dopamine D1 receptors in
schizophrenia revealed by PET. Nature 385:634–636
Peng S, Sun H, Zhang X, Liu G, Wang G (2014) Effects of selective
phosphodiesterases-4 inhibitors on learning and memory: a review
of recent research. Cell Biochem Biophys 70:83–85
Pérez-Torres S, Miró X, Palacios JM, Cortés R, Puigdoménech P,
Mengod G (2000) Phosphodiesterase type 4 isozymes expression
in human brain examined by in situ hybridization histochemistry
Psychopharmacology
and [3 H] rolipram binding autoradiography: comparison with mon-
key and rat brain. J Chem Neuroanat 20:349–374
Rodefer JS, Saland SK, Eckrich SJ (2012) Selective phosphodiesterase
inhibitors improve performance on the ED/ID cognitive task in rats.
Neuropharmacology 62:1182–1190
Rutten K, Prickaerts J, Blokland A (2006) Rolipram reverses
scopolamine-induced and time-dependent memory deficits in object
recognition by different mechanisms of action. Neurobiol Learn
Mem 85:132–138
Rutten K, Basile JL, Prickaerts J, Blokland A, Vivian JA (2008) Selective
PDE inhibitors rolipram and sildenafil improve object retrieval per-
formance in adult cynomolgus macaques. Psychopharmacology
196:643–648
Rutten K, Van Donkelaar EL, Ferrington L, Blokland A, Bollen E,
Steinbusch HW et al (2009) Phosphodiesterase inhibitors enhance
object memory independent of cerebral blood flow and glucose
utilization in rats. Neuropsychopharmacol 34:1914–1925
Taylor JR, Birnbaum S, Ubriani R, Arnsten AF (1999) Activation of
cAMP-dependent protein kinase A in prefrontal cortex impairs
working memory performance. J Neurosci 19(18):RC23–RC23
Van der Aart J, Salinas C, Dimber R, Pampols-Maso S, Weekes AA,
Tonkyn J, et al. (2017) Quantification of human brain PDE4 occu-
pancy by GSK356278: A [11C](R)-rolipram PET study. J Cerebr
Blood Flow Metab 0(0): 1–8
Van Duinen M, AO Reneerkens, Lambrecht L, Sambeth A, Rutten BP,
Van Os J, et al. (2015) Treatment of cognitive impairment in
schizophrenia: potential value of phosphodiesterase inhibitors in
prefrontal dysfunction. Curr Pharm Des 21: 3813–3828
Van Duinen M, Heckman PRA, Vanmierlo T, Sambeth A, Ogrinc F, Tsai
M, Lahu G, Uz T, Blokland A, Prickaerts J (2017) The PDE4-
inhbitor roflumilast improves episodic memory: findings from a
translational perspective. Eur Neuropsychopharmacol 27:S1024–
S1025
Van Duinen MA, Sambeth A, Heckman PR, Smit S, Tsai M, Lahu G, Uz
T, Blokland A, Prickaerts J (2018) Acute administration of
roflumilast enhances immediate recall of verbal word memory in
healthy young adults. Neuropharmacology 131:31–38
Vanmierlo T, Creemers P, Akkerman S, van Duinen M, Sambeth A, De
Vry J et al (2016) The PDE4 inhibitor roflumilast improves memory
in rodents at non-emetic doses. Behav Brain Res 303:26–33
Wallace TL, Ballard TM, Pouzet B, Riedel WJ, Wettstein JG (2011)
Pharmacology, biochemistry and behavior drug targets for cognitive
enhancement in neuropsychiatric disorders. Pharmacol Biochem
Behav 99:130–145
Wechsler D (1997) Wechsler memory scale - Third Edition. The
Psychological Corporation, San Antonio
Zhang HT, O’Donnell JM (2000) Effects of rolipram on scopolamine-
induced impairment of working and reference memory in the radial-
arm maze tests in rats. Psychopharmacology 150:311–316
Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, O’Donnell JM
(2000) Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses
memory deficits associated with NMDA receptor antagonism.
Neuropsychopharmacology 23:198–204
Psychopharmacology
